1	Performance of three diagnostic tests for tuberculosis
2	among Human Immunodeficiency Virus (HIV) patients
3	presenting to a health facility in an informal urban
4	settlement in Nairobi, Kenya.

5 Eunita A. Ochola¹, Marshal M. Mweu²

6 ¹ Department of Medical Laboratory Science, Faculty of Health Sciences, South Eastern

- 7 Kenya University, Kitui, Kenya
- 8 ²Department of Public and Global Health, Faculty of Health Sciences, University of Nairobi,

9 Nairobi, Kenya

10

11	*Corres	ponding	author
----	---------	---------	--------

- 12 Email: eochola@seku.ac.ke
- 13 [¶]These authors contributed equally to this work.

14

15

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

16 Abstract

The absence of an accurate reference test complicates the evaluation of tuberculosis (TB) diagnostic tests among people living with Human Immunodeficiency Virus (PLWHIV). The objective of this study was to estimate (using Bayesian latent class models [BLCM]) the sensitivity (Se), specificity (Sp) and negative and positive predictive values (NPV and PPV) of sputum smear microscopy (SSM), Xpert Ultra and lipoarabinomannan antigen (LAM) tests for TB among PLWHIV in Nairobi, Kenya.

This cross-sectional study enrolled a total of 190 patients aged ≥ 18 years with presumptive
TB seeking treatment at the Kibra Community Health Center Comprehensive Care Centre
(CCC) clinic between September 2022 and March 2023. The diagnostic data obtained from
the three tests were analysed using a BLCM framework to derive accuracy estimates of the
three diagnostic tests.

The Xpert Ultra assay registered a higher Se (85.0; 95% PCI [41.4 - 99.4]) compared to
LAM (26.8; 95% PCI [4.7 - 67.6]) and SSM (56.7 [16.4 - 97.4]). However, SSM had the
highest Sp (99.6; 95% PCI [97.7 - 100.0]). The Xpert Ultra assay yielded the highest overall
combination of Se and Sp at 80.8% (95% PCI [37.0 - 96.5]). On predictive values, SSM
recorded the highest PPV at 84.5% (95% PCI [38.4 - 99.4]). Nonetheless, all the tests
exhibited noticeably high NPVs (>96%).

An optimal testing approach in this low-prevalence TB setting could entail an initial screening with the more sensitive Xpert Ultra test, with any resultant positives retested with the more specific SSM test - a two-test serial testing strategy.

37

39 Introduction

Worldwide, tuberculosis (TB) ranks among the main causes of mortality from a single 40 pathogenic agent(1). Human Immunodeficiency Virus (HIV) infected patients have a 20 to 30 41 fold higher probability of contracting TB(2). As of 2017, approximately 9% of the 10 million 42 new TB cases were people living with HIV (PLWHIV), with Africa accounting for a 72% 43 disproportionate share(3). Kenya ranks amid the high-TB burden nations whose primary 44 45 cause of death is TB(4). 46 47 In Kenya, pulmonary TB is the most prevalent type and 66% of TB cases occur among those aged ≤ 44 years(5). In line with the national TB diagnosis and treatment guidelines, the 48 commencement of TB treatment is informed by bacteriological confirmation of Mycobacterium 49

tuberculosis (MTB). However, clinical diagnosis where bacteriological confirmation is not
possible may suffice for initiation of treatment(6).

52

53 Sputum smear microscopy (SSM) has been the main diagnostic tool for TB especially in 54 developing countries (7). It is extensively used because it is easy to run, rapid, inexpensive 55 and has high specificity (Sp) for TB diagnosis (8, 9). Nevertheless, it has a limited sensitivity 56 (Se) of approximately 10,000 TB bacilli/ml of sputum. Notably, its poor Se poses a challenge 57 for diagnosis of TB in PLWHIV since they have fewer bacilli in their sputum (10).

58

59 Diagnostic tests with improved Se and rapid turnaround time among PLWHIV could lead 60 to improved patient outcomes, reduced mortality and lower progressive transmission of TB 61 (11). The real time polymerase chain reaction (PCR) assay utilizing the gene Xpert platform 62 such as Xpert Ultra, offers better test Se and Sp with ability to discriminate between 63 tuberculous and non-tuberculous mycobacteria(12). Moreover, the test may detect at least

64 15.6 Colony forming units (CFU) of MTB/ml in sputum samples in under two hours(12).
65 Nonetheless, the technical and operational cost implications of the diagnostic test in resource66 limited settings remain a challenge(13, 14).

67

With sputum production among HIV infected individuals being limited(15), the need for 68 alternative biological specimens for the diagnosis ΤB arises. 69 of А rapid detecting 70 immunochromatographic test the Mycobacterium cell wall antigen lipoarabinomannan (LAM) in urine samples is available as a point-of-care test for TB (16). 71 The test is easy to run, has no need for specialized equipment or laboratory facilities and 72 73 results are obtainable within 25 minutes - rendering the test field applicable. Moreover, 74 among PLWHIV, the test displays high Sp, with Se increasing with diminishing CD4 counts(15-18). 75

76

Diagnostic studies evaluating the performance of SSM, Xpert Ultra and TB LAM among 77 78 PLWHIV have previously been conducted globally (19, 20). A major shortcoming of these 79 evaluations is that the index tests were evaluated against imperfect reference standards, thus 80 introducing bias in the accuracy estimates of the evaluated tests(21). A superior alternative 81 involves the use of latent class models fit using Bayesian methods that allow for concurrent 82 evaluation of Se and Sp of two or more tests without prior knowledge of the unobserved disease status of individuals(22). Consequently, the objective here was to estimate the Se and 83 84 Sp as well as the predictive values of SSM, Xpert Ultra and LAM tests for TB among HIV patients within an informal outpatient setting using a Bayesian latent class model (BLCM) 85 framework. 86

88

89 Materials and Methods

90 Study setting, design and population.

91 The study was carried out at the Kibra Community Health Centre; a level three state-run 92 facility located in the southern part of Nairobi. Notably, the facility serves an immediate large 93 informal-settlement population characterised by a high dual burden of HIV/AIDS and TB, 94 which are leading causes of mortality in slums(23). It registers around150-200 out-patients 95 daily, conducts approximately 50-60 deliveries monthly and offers comprehensive care clinic 96 (CCC) services to over 1,500 patients per month.

97 A facility-based cross-sectional study was employed to evaluate the performance of the three
98 diagnostic tests for TB. The rationale for the choice of this design stems not only from the
99 descriptive nature of the study but also the ease of recruitment of study participants
100 presenting to the CCC clinic for care.

101 Sample size and participant selection

102 The required sample size was derived using the McNemar's sample size formula for paired103 proportions(24):

104
$$n_{per \ test} = \left(\frac{Z_{\alpha/2}\sqrt{p_{disc}} + Z_{\beta}\sqrt{p_{disc} - p_{diff}^2}}{p_{diff}}\right)^2$$

105
$$p_{disc} = (1 - Se_1) + (1 - Se_2)$$

106
$$p_{diff} = (1 - Se_1) - (1 - Se_2)$$

108 Where: $n_{per \ test}$ = sample size required for each test, $Z_{\frac{\alpha}{2}}(1.96)$ is the value required for the 109 two-sided 95% confidence level, and Z_{β} (-0.84) is the value specifying the desired power of 110 80%. Se_1 and Se_2 are estimates of Se of the Gene xpert MTB/RIF and SSM respectively from 111 literature i.e. Se_1 is 90.3% and Se_2 is 67.1% (25).

As per the above mentioned figures, a total sample size of 190 was generated, after an upwardadjustment by 5% to account for non-response.

To obtain the required sample, individuals visiting the hospital's CCC clinic were systematically random sampled in their order of arrival where every seventh person (after an initial random start) who met the eligibility criteria was selected. Eligibility was limited to PLWHIV (symptomatic or asymptomatic for TB) aged ≥ 18 years who at the time of recruitment (28th September 2022- 31st March 2023) were visiting the CCC at the facility for care and consented to participation in the study. Importantly, recruitment followed triage by the clinic nurse and examination by a physician.

121 Ethical considerations

Written permission to conduct this study was obtained from and approved from the Kenyatta
National Hospital -University of Nairobi Ethics and Research Committee (Ref. No.
KNH/ERC/R/145 and KNH/ ERC/Mod & SAE/347), the Nairobi metropolitan Services
(Ref. No. EOP/NMS/HS/222), as well as the National Commission for Technology and
Innovation (NACOSTI) (Ref. No. NACOSTI/P/21/14098). Moreover, a written informed
consent was secured from individual patients prior to enrolling them into the study.

129 Sample collection

Participants were provided with clear instructions on collection of urine and sputum samples.
Of note, the LAM and SSM tests were carried out immediately at the facility's laboratory by
a trained laboratorian. Samples for the Xpert Ultra assay were stored in cooler boxes and
delivered to a referral laboratory for processing. On enrolment, the participants'
sociodemographic characteristics (age, sex, marital status, level of education, area of
residence, occupation and highly active antiretroviral therapy status (HAART) were
recorded.

137

138 Target condition

The infection (latent) status being targeted by the three tests (Xpert Ultra, SSM and LAM)
constitutes a respiratory or urine sample carrying either the live MTB, its DNA or cell wall
LAM antigen at any concentration.

142 Sputum Smear Microscopy (SSM)

This was performed as per standard guidelines(7). Briefly, a sputum smear covering 2cm by 143 144 1 cm on the centre of the slide was prepared immediately after receipt of the sample. The smears were then stained with the primary stain 1% Carbol fuchsin for a period not exceeding 145 10 minutes. Decolourisation was then performed by flooding the slides with 25% sulphuric 146 acid for 3 minutes and subsequently the counterstain 0.1% methylene blue was added for 1 147 minute. Slides were rinsed before every staining stage and excess water drained by gently 148 tilting each slide. The slides were thereafter examined under a light microscope at 100x 149 magnification. Mycobacterium quantification was achieved by counting the acid fast bacteria 150 (AFB) as per the International Union Against TB and Lung Disease recommended grading 151

of sputum smear microscopy(7). For analytical purposes, AFB counts above zero constituteda positive result; otherwise negative.

154 Gene Xpert Mycobacterium/ Rifampicin Ultra (Xpert Ultra)

This was carried out as described elsewhere(26). Briefly, a sample reagent (a constitution of 155 156 sodium hydroxide and Isopropanol) was added into a sputum sample in a ratio of 2:1 for liquefaction and inactivation of the sputum. The mixture was then vigorously shaken and 157 incubated at room temperature for 15 minutes. The liquefied specimen was afterwards 158 159 pipetted into the test cartridge (Cat. No. 42722, Cepheid). The pre-labelled test cartridge was loaded into the MTB/RIF test platform (Cepheid) where automated testing commenced. The 160 semi-nested real time amplification and detection occurred in an integrated reaction tube and 161 the results were printed. Results were interpreted as positive when MTB was detected. 162

163 Lateral Flow Urine Lipoarabinomannan (LAM)

Alere DetermineTM TB LAM antigen kit (Cat No. 238237, Abbott Diagnostics Scarborough) was used to test for the presence of TB LAM antigen in collected urine samples. This was executed as per the instructions in the Alere DetermineTM TB LAM antigen manual (27). A total of 60ul of urine was added into the strip sample well. In order to allow for the urine to flow towards both the test and control windows, the strip was incubated at room temperature for 25 minutes. A positive result was denoted by the appearance of two colour bands; one band on the control line being indicative of a negative result.

171 Statistical analysis

A Bayesian latent class model fitted in OpenBUGS v3.2.2(28) but called from R software
through the 'BRugs' package(29) was used to estimate the TB prevalence, Se and Sp of the
three tests together with their predictive values. The guidelines for standards for reporting

diagnostic accuracy studies that use BLCMs were used to inform the analysis and reportingof the results (30). The model code is available as underlying data(31).

177

Three assumptions are necessary when fitting a BLCM(32). Firstly, the tests should be 178 conditionally independent given the TB infection status. This was met since microscopy 179 targets the live bacterium, Xpert Ultra amplifies and detects the Mycobacterium DNA and TB 180 181 LAM detects the Mycobacterium cell wall LAM antigen. Hence, the probability of testing 182 either positive or negative on one diagnostic tool did not depend on the outcome of the other 183 tests. Secondly, the Se and Sp of the tests being evaluated should be constant across the subpopulations studied. With a single target population, as was the case here, the tests' 184 constancy premise was likely to be upheld. Thirdly, the target population should consist of 185 two or more subpopulations with different prevalences. In situations where only a single 186 population exists, at least three tests are necessary to provide sufficient degrees of freedom to 187 achieve model identifiability (30) 188

189

A multinomial distribution was assumed for the counts (0) of the different test combinations
(e. g. +, +, +) and took the form below:

192

$O \mid Se_i Sp_i P \sim multinomial (Prob, n)$

193 Where Se_i and Sp_i reflect the specific test characteristics of the individual tests (i = 1, 2, 3), 194 P denotes the prevalence for the singular population, Prob is a vector of probabilities of 195 observing different test combinations and n denotes the sample size of the study population. 196 As an illustration, the probability of an individual testing positive on all three tests is given 197 by:

199
$$Prob = \Pr\left(T_{1}^{+}T_{2}^{+}T_{3}^{+}|D^{+}) + \Pr\left(T_{1}^{+}T_{2}^{+}T_{3}^{+}\right|D^{-}\right)$$

200
$$= Se_1 Se_2 Se_3 P + [1 - Sp_1][1 - Sp_2][1 - Sp_3][1 - P]$$

With three tests, a total of seven degrees of freedom was sufficient to estimate the required seven parameters (the Se and Sp of the three tests together with the single population prevalence). Since there was no reliable prior information for any of the tests, uninformative priors (*beta* (1, 1)) were used as initial parameters for the model.

205 The positive predictive value (PPV) and negative predictive value (NPV) of the test (*i*) were206 estimated as follows:

207
$$ppv_i = PSe_i / (PSe_i + [1 - P][1 - Sp_i])$$

208
$$npv_i = [1-P]Sp_i/(P[1-Se_i] + [1-P]Sp_i)$$

Two Markov Chain Monte Carlo chains each having different values were used to initialise the Bayesian model. Convergence of the chains was then evaluated via the time series plots of selected variables and the Gelman-Rubin diagnostic plots. The posterior distributions of the test estimates (Se, Sp and the predictive values) and the population prevalence were reported as the median and the associated 95% posterior credible intervals (PCI). The Youden index which is a measure of a test's overall diagnostic ability was also computed as : Se + Sp - 1(33).

216 **Results**

217 Of the 190 participants, two were unable to provide all the required samples and were thus 218 excluded from the analysis. Another five were excluded on the basis of their Xpert Ultra 219 results being invalid.

The sociodemographic characteristics and information on HAART status is as shown in Table 1. The median age of the participants was 43 years (Range: 19 - 82 yrs). The majority of participants were female (64.0%, n=117), married (60.7%, n=111), with only 2.2% (n=4)

- 223 lacking a formal education. A substantial percentage of the participants was on HAART
- **224** (97.5%, n=178).

225

- 226 Table 1: Summary statistics on the sociodemographic characteristics and information
- 227 on HAART status for HIV patients presenting to a primary health facility in an
- 228 informal settlement, Nairobi County, Kenya. (n=183)

Variable	Values	Median	Range	Frequency n (%)
Age				
		43	19-82	
Weight				
		60	40-101	
Sex				
	Male			66(36.1)
	Female			117(64.0)
Marital status				
	Married			111(60.7)
	Single			50(27.3)
	Separated/ divorced			18(9.8)
	Widowed			4(2.2)
Level of education				
	None			4(2.2)
	Primary			91(49.7)
	Secondary			69(37.7)
	Tertiary			19(10.4)
Area of residence				
	Formal			60(32.8)
	Informal			123(67.2)
Occupation				
	Employed			67(36.6)
	Unemployed			116(63.4)
HAART				
	Naïve			5(2.7)
	Experienced			178(97.3)

229 HAART; Highly Active Antiretroviral Therapy

231 The cross-tabulated counts of the tests' outcomes are displayed in Table 2.

- 232 Table 2: Cross- classified results for LAM, Xpert Ultra and SSM tests for diagnosis of
- 233 TB among PLWHIV presenting to the Kibra Community Health Centre CCC clinic,
- 234 Nairobi County, Kenya. (n=183)

Cross-tabulated counts of the three test outcomes									
	Test outcome	es combi	nations	s (LAM,	XPER	F ULT	RA & S	SM)	
Stratum									Total (%)
	+ + +	+ + -	+ -+	- + +	+	- + -	+		
Single population	1	1	0	3	21	8	0	149	183 (100%)
235 LAM; Lipoari	bomannan, SSM	; Sputum	n Smear	Microsc	ору				

236

237 The estimates of the Se and Sp of the three tests, along with their respective predictive values and the prevalence of MTB infection are shown in Table 3. The Xpert Ultra assay registered 238 a higher Se (85.0; 95% PCI [41.4 - 99.4]) compared to LAM (26.8; 95% PCI [4.7 - 67.6]) 239 and SSM (56.7 [16.4 - 97.4]). However, SSM displayed the highest Sp (99.6; 95% PCI [97.7 240 -100.0]). As per the Youden indices, Xpert Ultra yielded the highest overall combination of 241 Se and Sp at 80.8% (95% PCI [37.0 - 96.5]). On predictive values, SSM recorded the highest 242 PPV at 84.5% (95% PCI [38.4 - 99.4]). Nonetheless, all the tests exhibited noticeably high 243 NPVs (>96%). The true prevalence of MTB infection in this HIV-infected outpatient 244 population was 4.1% (95% PCI [1.2 - 11.2]). 245

Table 3. Estimates of prevalence, sensitivity, and specificity of LAM, Gene Xpert
Ultra, and SSM tests for MTB infection among HIV patients as well as their
corresponding predictive values and Youden indices.

250	Parameter	Estimate (95% PCI)
	Se _{LAM}	26.8(4.7-67.6)
	Se_{Xpert}	85.0 $(41.4 - 99.4)$
	Se _{SSM}	56.7 (16.4 - 97.4)
	Sp _{LAM}	87.6 (82.1 - 92.0)
	Sp_{Xpert}	96.0 (91.6 - 99.6)
	Sp _{SSM}	99.6 (97.7 – 100)
	Р	4.1(1.2 - 11.2)
	NPV _{LAM}	96.7 (89.7 – 99.3)
	NPV _{Xpert}	99.4 (95.1 - 100)
	NPV _{SSM}	98.3 (91.5 – 100)
	PPV _{LAM}	8.3(1.1 - 26.8)
	PPV _{Xpert}	45.3(13.5 - 94.8)
	PPV _{SSM}	84.5 (38.4 - 99.4)
	Y.index _{LAM}	14.3 (-8.9 - 55.6)
	$Y.index_{Xpert}$	80.8 (37.0 - 96.5)
	Y.index _{SSM}	56.2(15.7 - 96.8)

251 Se; Sensitivity, Sp; Specificity, PCI; Posterior confidence interval, LAM; Lipoaribomannan, P;

252 Prevalence, NPV; Negative predictive value, PPV; Positive predictive values

254

255 Discussion

This study has utilized Bayesian latent class analysis for the estimation of the accuracy of SSM, Xpert Ultra and LAM tests (together with their corresponding predictive values) for the diagnosis of TB infection among PLWHIV. This is a key strength in this study since BLCM allows for the estimation of index tests' characteristics devoid of classification errors typically inherent in traditional evaluation studies employing the use of imperfect reference standards(21). Accordingly, the estimates obtained from this study can be considered generalisable to settings with similar MTB burden among PLWHIV.

263

On Se, Xpert Ultra assay recorded the highest Se of the three tests. This result is in agreement 264 265 with previous reports that demonstrated the superiority of Xpert Ultra Se over other tests in 266 TB screening and diagnosis among PLWHIV in outpatient settings. In particular, in a systematic review involving studies conducted in high TB prevalence settings among 267 PLWHIV, the Xpert Ultra test Se ranged between 81% - 90%(20). The superiority of the 268 test's Se owes to its low detection limit of tubercle bacilli (16 CFU/ ml of sputum)(34) 269 compared to SSM whose threshold is 5,000 - 10,000 CFU/ ml of sputum (35) and LAM at \sim 270 2000 CFU / ml (36, 37). 271

The LAM test exhibited the lowest Se in the diagnosis of TB in the present study. This
performance is comparable with findings from studies carried out in other outpatient settings.
For instance, among existing, ART-naïve and newly diagnosed HIV patients presenting to
outpatient facilities in LMICs, LAM's Se was found to range between 25% - 30% (17, 36, 38,
39). Notably, an inverse relationship has been demonstrated, with LAM's test Se increasing
with reducing CD4 counts among critically ill HIV patients(17, 40). LAM Se was observed

to be at its highest ($\geq 65\%$) among patients with CD4 counts <50 cells/ul and Se of 35%-55% 278 for patients with CD4 counts between 100 and 200 cells/ul respectively (17, 40). Increased 279 uptake of ARV therapy in the present study setting may have contributed to improved CD4 280 counts in the patient population resulting in a low Se of the LAM test - underscoring its 281 limited utility in this setting. SSM registered a test Se of 56.7% which falls within the 18% -282 94.2% range observed in other studies(41, 42). The wide variability in performance is 283 attributable to the number of CFUs available in a sample, with Se increasing with higher 284 CFUs. Moreover, the test Se is also highly dependent on user expertise and other technical 285 and operational factors (42). 286

As regards Sp, SSM exhibited the highest which is consistent with findings from studies carried out in outpatient settings among PLWHIV(43, 44). The Sp displayed by LAM is also corroborated by findings from other studies carried out in similar low-resource settings where specificities ranging between >90%-100% were registered (36, 38, 45, 46). Xpert Ultra Sp is in agreement with specificities found in other similar settings where the test Sp was reported to range between 78%- 96% (20, 47).

293 False negative and false positive results compromise Se and Sp estimates respectively. As for 294 LAM and SSM, false negative results are more likely to occur in patients with bacterial load below the tests detection limits(48). Additionally, LAM is more likely to give false negative 295 results in patients who have already received anti-TB treatment(49). False positive results by 296 LAM have been demonstrated in samples contaminated with non-Mycobacterial pathogens 297 such as Nocardia and Candida spp. that similarly exhibit LAM-like glycoprotein antigen(46). 298 299 SSM is also unable to distinguish MTB from other smear-positive Mycobacteria spp.(50). False 300 positives by Xpert Ultra could be attributable to detection of MTB DNA in patients recently 301 cured of TB (44).

303 Notably, in this population, the three tests' sensitivities displayed wide credible intervals 304 (signifying low precision of the estimates) since there were few diseased individuals. In 305 contrast, the tests' Sps demonstrated high precision owing to the significant number of truly 306 non-diseased individuals. Overall, in this low-prevalence TB setting, Xpert Ultra affords good 307 promise for informing treatment and surveillance for TB among PLWHIV.

308

With low MTB prevalence (4.1%), generally low PPVs but high NPVs would be anticipated 309 for the three tests. These estimates signify a stronger confidence in a negative than a positive 310 311 test result. Consequently, in this low-prevalence setting where the probability of false 312 positives is highly contemplated, a multiple testing strategy with serial interpretation of the test results may be necessary in order to raise the confidence in a positive test result. This 313 could entail an initial screening with the more sensitive Xpert Ultra test, with any resulting 314 positives followed up with the more specific SSM test. This approach should assure that false 315 positive individuals are not unnecessarily subjected to protracted therapy for TB. 316

317 Conclusions

The Xpert Ultra assay registered the highest Se compared to SSM and LAM. However, SSM registered the highest Sp and thus PPV estimate. Nevertheless, the three tests recorded similar NPVs. Owing to the low prevalence of TB in the study setting, an optimal testing approach could entail an initial screening with the more sensitive Xpert Ultra assay, with any resultant positives re-tested with the more specific SSM test – a serial testing strategy - to bolster the overall PPV of a TB testing and surveillance programme.

325 Acknowledgments

- 326 The authors sincerely thank the study participants, the administration and staff at Kibra
- 327 Community Health Centre for making it possible to realise this research work.

329)
-----	---

330 References

WHO. World Health Organization annual report 2019 WHO Country Office
 Lebanon: health for all. Cairo: World Health Organization. Regional Office for the Eastern
 Mediterranean, 2020 2020-06. Report No.: 9789290223207.

334

WHO. WHO meeting report of a technical expert consultation: non-inferiority
 analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health
 Organization. Geneva: 2017.

338

339 3. World Health O. Global tuberculosis report 2018. Geneva: World Health
340 Organization, 2018 2018. Report No.: 9789241565646.

341

Enos M, Sitienei J, Ong'ang'o J, Mungai B, Kamene M, Wambugu J, et al. Kenya
 tuberculosis prevalence survey 2016: Challenges and opportunities of ending TB in Kenya.
 PLoS One. 2018;13(12):e0209098. doi: 10.1371/journal.pone.0209098. PubMed PMID:
 30586448; PubMed Central PMCID: PMCPMC6306266.

346

347 5. MOH. Kenya Tuberculosis Prevalence Survey: Final Survey Report. Nairobi, Kenya:
348 2016.

349

350 6. MOH. Guidelines for management of Tuberculosis and Leprosy in Kenya. Nairobi,351 Kenya: 2013.

352	7. Dawson D, Akhtar M, Bretzel G, Boulahbal F, Fattorini L, Feldmann K, et al.
353	Technical guide sputum examination for Tuberculosis by direct microscopy in low income
354	countries. 2000.

355

Akanbi MO, Achenbach C, Taiwo B, Idoko J, Ani A, Isa Y, et al. Evaluation of gene
 xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort
 study. BMC Pulm Med. 2017;17(1):87. doi: 10.1186/s12890-017-0430-6. PubMed PMID:
 28558662; PubMed Central PMCID: PMCPMC5450144.

360

361 9. Gelaw B, Shiferaw Y, Alemayehu M, Bashaw AA. Comparison of loop-mediated
362 isothermal amplification assay and smear microscopy with culture for the diagnostic accuracy
363 of tuberculosis. BMC Infect Dis. 2017;17(1):79. doi: 10.1186/s12879-016-2140-8. PubMed
364 PMID: 28095790; PubMed Central PMCID: PMCPMC5240421.

365

Behr MA, Warren SA, Salamon H, Hopewell PC, de Leon AP, Daley CL, et al.
Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast
bacilli. The Lancet. 1999;353(9151):444-9. doi: 10.1016/s0140-6736(98)03406-0.

369

370 11. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R)
371 MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane
372 Database Syst Rev. 2014(1):CD009593. doi: 10.1002/14651858.CD009593.pub3. PubMed
373 PMID: 24448973; PubMed Central PMCID: PMCPMC4470349.

374

375 12. Chakravorty S SA, Rowneki, M PH, Cao Y, Ryan J, Banada PP,, Deshpande S SS, Gall
376 A, Glass J,, Krieswirth B SS, Nabeta P,, Tukvadze N RC, Skrahina A, Tagliani E,, Cirillo DM

377	DA, Denkinger CM, Persing, et al. The new Xpert MTB/RIF Ultra: improving detection of
378	Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care
379	testing. American Society for Microbiology. 2017;Volume 8(Issue 4).
380	
381	13. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, N D. Xpert® MTB/RIF assay
382	for pulmonary tuberculosis and rifampicin resistance in adults (Review). JohnWiley & Sons,
383	Ltd. 2014. doi: 10.1002/14651858.CD009593.pub3.

384

385 14. Stephen D. Lawn, Sophie V. Brooks, Kranzer K, MPN, Andrew Whitelaw, Monica
386 Vogt, et al. Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before
387 Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study. PLOS
388 MEDICINE. 2011;8. doi: 10.1371/journal.pmed.1001067.

389

Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis
of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin
Pulm Med. 2010;16(3):262-70. doi: 10.1097/MCP.0b013e328337f23a. PubMed PMID:
20375787; PubMed Central PMCID: PMCPMC5454484.

394

Huerga H, Ferlazzo G, Bevilacqua P, Kirubi B, Ardizzoni E, Wanjala S, et al. 395 16. Incremental Yield of Including Determine-TB LAM Assay in Diagnostic Algorithms for 396 Ambulatory HIV-Positive Patients 397 Hospitalized and in Kenya. PLoS One. 2017;12(1):e0170976. doi: 10.1371/journal.pone.0170976. PubMed PMID: 28125693; 398 399 PubMed Central PMCID: PMCPMC5268475.

401 17. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Diagnostic accuracy
402 of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected
403 adults: a prospective, clinic-based study. BMC infectious diseases. 2014;14:110. Epub
404 2014/02/28. doi: 10.1186/1471-2334-14-110. PubMed PMID: 24571362; PubMed Central
405 PMCID: PMCPmc3944827.

406

Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. 407 18. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive 408 adults. Cochrane Database Rev. 409 Syst 2016(5):CD011420. doi: 410 10.1002/14651858.CD011420.pub2. PubMed PMID: 27163343; PubMed Central PMCID: 411 PMCPMC4916932.

412

413 19. Cattamanchi A, Dowdy DW, Davis JL, Worodria W, Yoo S, Joloba M, et al.
414 Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients
415 suspected of having pulmonary tuberculosis. BMC Infect Dis. 2009;9:53. doi: 10.1186/1471416 2334-9-53. PubMed PMID: 19419537; PubMed Central PMCID: PMCPMC2690598.

417

20. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al.
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in
adults with presumptive pulmonary tuberculosis. The Cochrane database of systematic
reviews. 2021;2:CD009593. doi: 10.1002/14651858.CD009593.pub5. PubMed PMID:
33616229.

423

424 21. Claes Enøe, Marios P Georgiadis, Johnson WO. Estimation of sensitivity and
425 specificity of diagnostic tests and disease prevalence when the true disease state is unknown,
426 Preventive Veterinary Medicine. 2000;45(1-2):61-81.

427	22. Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease prevalence and the
428	parameters of diagnostic tests in the absence of a gold standard. American journal of
429	epidemiology. 1995;141(3):263-72. Epub 1995/02/01. doi:
430	10.1093/oxfordjournals.aje.a117428. PubMed PMID: 7840100.
431	
432	23. Beguy D, Elung'ata P, Mberu B, Oduor C, Wamukoya M, Nganyi B, et al. Health &
433	Demographic Surveillance System Profile: The Nairobi Urban Health and Demographic
434	Surveillance System (NUHDSS). International journal of epidemiology. 2015;44(2):462-71.
435	doi: 10.1093/ije/dyu251. PubMed PMID: 25596586.
436	
437	24. Connor RJ. Sample size for testing differences in proportions for the paired-sample
438	design. Biometrics. 1987;43(1):207-11. Epub 1987/03/01. PubMed PMID: 3567305.
439	
440	25. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility,
441	diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for
442	diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. The
443	Lancet. 2011;377(9776):1495-505. doi: 10.1016/s0140-6736(11)60438-8.
444	
445	26. Raja S, Ching J, Xi L, Hughes SJ, Chang R, Wong W, et al. Technology for automated,
446	rapid, and quantitative PCR or reverse transcription-PCR clinical testing. Clin Chem.
447	2005;51(5):882-90. doi: 10.1373/clinchem.2004.046474. PubMed PMID: 15746302.
448	
449	27. Abbott. Determine TM TB LAM Ag SAVING LIVES with early TB diagnosis in people
450	with HIV. 2010.

451	28. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: Evolution, critique
452	and future directions. Stat Med. 2009;28(25):3049-67. doi: 10.1002/sim.3680. PubMed
453	PMID: 19630097.
454	
455	29. Thomas A, O'Hara, R, Ligges, U & Sturtz,. 'Making BUGS open', R News.,. 2006.
456	
457	30. Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, et al.
458	STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use
459	Bayesian Latent Class Models. Preventive veterinary medicine. 2017;138:37-47. doi:
460	10.1016/j.prevetmed.2017.01.006. PubMed PMID: 28237234.
461	
462	31. Eunita A. Replication Data for: Evaluation of the performance of three diagnostic tests
463	for Tuberculosis among HIV patients presenting to a health facility in an informal urban
464	settlement in Nairobi county, Kenya. DRAFT VERSION ed: Harvard Dataverse; 2023.
465	
466	32. Hui SL, Walter SD. Estimating the Error Rates of Diagnostic Tests. Biometrics.
467	1980;36(1):167-71. doi: 10.2307/2530508.
468	
469	33. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal Cut-Point and Its
470	Corresponding Youden Index to Discriminate Individuals Using Pooled Blood Samples.
471	Epidemiology. 2005;16(1):73-81.
472	
473	34. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of
474	Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient
472 473	34. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection
4/4	Mycobacterium tuberculosis and ritampin resistance by use of on-demand, near-patient

475 technology. Journal of clinical microbiology. 2010;48(1):229-37. doi: 10.1128/JCM.01463-09.

476 PubMed PMID: 19864480; PubMed Central PMCID: PMC2812290.

Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al.
Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast
bacilli. Lancet. 1999;353(9151):444-9. doi: 10.1016/s0140-6736(98)03406-0. PubMed PMID:
9989714.

481

36. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, et
al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIVinfected adults. Journal of acquired immune deficiency syndromes. 2014;66(3):270-9. doi:
10.1097/QAI.000000000000151. PubMed PMID: 24675585; PubMed Central PMCID:
PMC4146703.

487

37. Kawasaki M, Echiverri C, Raymond L, Cadena E, Reside E, Gler MT, et al. 488 489 Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients 490 with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. PLoS Med. 2019;16(4):e1002780. doi: 10.1371/journal.pmed.1002780. PubMed PMID: 30978194; 491 492 PubMed Central PMCID: PMC6461223 following competing interests: MK, TO, RI, RH and KK are employees of Otsuka Pharmaceutical Co., Ltd. YL is an employee of Otsuka 493 494 Pharmaceutical Development & Commercialization, Inc., which is a subsidiary of Otsuka 495 Pharmaceutical Co., Ltd. During the conduct of the clinical studies, MTG was an employee 496 of Otsuka (Philippines) Pharmaceutical Inc., which is a subsidiary of Otsuka Pharmaceutical Co., Ltd. The rest of the authors declare no conflicts of interest associated with this 497 498 manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. 499

500

501 38. Balcha TTW, N. Sturegard, E. Skogmar, S. Reepalu, A., Jemal ZH, Tibesso G, Schon
502 T, Bjorkman P. Detection of lipoarabinomannan in urine for identification of active

503	tuberculosis among HIV-positive adults in Ethiopian health centres. Tropical medicine &
504	international health : TM & IH. 2014;19(6):734-42. doi: 10.1111/tmi.12308. PubMed PMID:
505	24684481.
506	
507	39. Stephen D Lawn ADK, Monica Vogt, Robin Wood. Diagnostic accuracy of a low-cost,
508	urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis
509	before antiretroviral therapy: a descriptive study. 2012. doi: 10.1016/S1473-3099(11)70251-
510	1.

511

Aliasgar Esmail a, b Anil Pooran,a,b Natasha F. Sabur,a,c Mohammed Fadul,a,b
Mantaj S. Brar,d Suzette Oelofse,a,b, Michele Tomasicchio a, b Keertan Dhedaa,b,e,f. An
Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using
GeneXpert MTB/RIF and Alere Determine TB LAM Ag. Journal of clinical microbiology.
2020. doi: 10.1128/JCM.

517

518 41. Jean Claude Semuto Ngabonziza WS, Florence Mutua, Gabriela Torrea, Augustin
519 Dushime, Michel Gasana EA, Schifra Uwamungu, Alaine Umubyeyi Nyaruhirira, Dufton
520 Mwaengo and, Muvunyi CM. Diagnostic performance of smear microscopy and incremental
521 yield of Xpert in detection of pulmonary tuberculosis in Rwanda. BMC infectious diseases.
522 2016. doi: 10.1186/s12879-016-2009-x.

523

Mecky Matee LM, Tarja Lounasvaara, Wendy Wieland-Alter, Richard Waddell JL,
Muhammad Bakari, Reyn KPaCFv. Sputum microscopy for the diagnosis of HIV-associated
pulmonary tuberculosis in Tanzania. 2008. doi: 10.1186/1471-2458-8-68.

Page 26 of 30

527	43. Catharina C. Boehme MD, Pamela Nabeta, M.D., Doris Hillemann, Ph.D., Mark P.
528	Nicol, Ph.D.,, Shubhada Shenai PD, Fiorella Krapp, M.D., Jenny Allen, B.Tech., Rasim
529	Tahirli, M.D., Robert Blakemore, B.S.,, Roxana Rustomjee MD, Ph.D., Ana Milovic, M.S.,
530	Martin Jones, Ph.D., Sean M. O'Brien, Ph.D.,, David H. Persing MD, Ph.D., Sabine Ruesch-
531	Gerdes, M.D., Eduardo Gotuzzo, M.D., Camilla Rodrigues, M.D.,, David Alland MD, and
532	Mark D. Perkins, M.D. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance.
533	The New England Journal of Medicine. 2010;363.

534

535 44. Balcells ME, García P, Chanqueo L, Bahamondes L, Lasso M, Gallardo AM, et al.
536 Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago,
537 Chile. The international journal of tuberculosis and lung disease : the official journal of the
538 International Union against Tuberculosis and Lung Disease. 2012;16(10):1349-53. Epub
539 2012/08/07. doi: 10.5588/ijtld.12.0156. PubMed PMID: 22863872.

540

- 541 45. Paul K. Drain M, MPH1,2, Elena Losina, PhD1,3,4, Sharon M. Coleman, MS6, Janet
 542 Giddy, MBBCh7, Douglas Ross, MBBCh, MBA8, Jeffrey N. Katz, MD4, and Ingrid V.
 543 Bassett, MD, MPH. Value of Urine Lipoarabinomannan Grade and Second Test for
 544 Optimizing Clinic-based Screening for HIV-associated Pulmonary Tuberculosis. 2015.
- 545

46. Peter J, Theron G, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Test
characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected
outpatients under investigation for TB and able to self-expectorate sputum for diagnostic
testing. BMC infectious diseases. 2015;15:262. doi: 10.1186/s12879-015-0967-z. PubMed
PMID: 26156025; PubMed Central PMCID: PMC4495934.

552	47. Berhanu RH, David A, da Silva P, Shearer K, Sanne I, Stevens W, et al. Performance
553	of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary
554	Tuberculosis in a High-HIV-Burden Setting. Journal of clinical microbiology. 2018;56(12).
555	doi: 10.1128/jcm.00560-18.
556	
557	48. Saeed M, Rasheed F, Iram S, Hussain S, Ahmad A, Riaz S, et al. False Negativity of
558	Ziehl-Neelsen Smear Microscopy: Is the Scale-up the Worth It in Developing Countries?
559	Journal of the College of Physicians and SurgeonsPakistan : JCPSP. 2018;28(3):201-5. Epub
560	2018/03/17. doi: 10.29271/jcpsp.2018.03.201. PubMed PMID: 29544576.
561	
562	49. Nel JS, Lippincott CK, Berhanu R, Spencer DC, Sanne IM, Ive P. Does Disseminated
563	Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral
564	Flow Assay Results? A Retrospective Review. Clinical infectious diseases : an official
565	publication of the Infectious Diseases Society of America. 2017;65(7):1226-8. Epub
566	2017/06/03. doi: 10.1093/cid/cix513. PubMed PMID: 28575238.
567	
568	50. Maxwell Oluwole Akanbi, Chad Achenbach, Babafemi Taiwo, John Idoko, Agatha Ani,
569	Yetunde Isa, et al. Evaluation of gene xpert for routine diagnosis of HIV-associated
570	tuberculosis in Nigeria: A prospective cohort study. BMC Pulmonary medicine. 2017. doi:
571	10.1186/s12890-017-0430-6.

573 Supporting information

- 574 S1 File. Harvard Dataverse: Replication Data for: Performance of three diagnostic tests
- 575 for tuberculosis among HIV patients presenting to a primary care facility in an informal
- 576 settlement in Nairobi County, Kenya. <u>https://doi.org/10.7910/DVN/PYRPCQ(31)</u>